CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：CD19-Targeted Chimeric Antigen Receptor T-cell Therapy for Concomitant Diffuse Large B-cell Lymphoma and Multiple Myeloma.
CD19-Targeted Chimeric Antigen Receptor T-cell Therapy for Concomitant Diffuse Large B-cell Lymphoma and Multiple Myeloma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
多发性骨髓瘤（MM）和弥漫性大B细胞淋巴瘤（DLBCL）占每年确诊血液系统恶性肿瘤的很大比例，但二者同时发生于同一患者较为罕见。近年来，靶向CD19和B细胞成熟抗原的嵌合抗原受体（CAR）T细胞疗法获批并取得良好应答。本文报告一例患者：骨髓活检显示其患有MM，20%的骨髓细胞为λ轻链限制性浆细胞，且未见淋巴瘤累及骨髓；随后对右大腿肿块进行淋巴结活检，确诊DLBCL。患者接受靶向CD19的CAR-T 细胞治疗后，MM和DLBCL均未检出。据作者所知，这是首例报道同时患有MM和DLBCL并接受CD19靶向CAR-T 治疗的病例。
Multiple myeloma (MM) and diffuse large B-cell lymphoma (DLBCL) comprise a large fraction of hematologic malignancies diagnosed each year.
However, the co-occurrence of these conditions in the same patient is rare. CD19- and B-cell maturation antigen-targeted chimeric antigen receptor (CAR) T-cell therapies have been approved in recent years with promising responses.
Here, we present a patient who presented following a bone marrow biopsy that revealed MM with 20% lambda-restricted plasma cells with no evidence of lymphoma involvement in the marrow. A subsequent lymph node biopsy of a right thigh mass was done and revealed DLBCL. The patient received CD19-targeted CAR T-cell therapy and has no detectable MM or DLBCL. To our knowledge, this is the first case report in the literature describing a patient with concomitant MM and DLBCL who received CD19-targeted CAR T-cell therapy.
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。
